Key Highlights
- Clarity Pharmaceuticals Limited (ASX:CU6) reports that the last patient has completed final follow-up assessments in the Phase III AMPLIFY diagnostic trial.
- The trial enrolled about 220 participants with biochemical recurrence of prostate cancer and reached its target enrolment in March 2026.
- Topline data from AMPLIFY and the CLARIFY trial are expected in the first half of CY2027.
- The company has Breakthrough Therapy and Fast Track designations for 64Cu-SAR-bisPSMA and is starting submissions for a New Drug Application.
Clarity Pharmaceuticals Limited (ASX:CU6), a clinical-stage radiopharmaceutical company, has confirmed that the last participant in its Phase III AMPLIFY diagnostic trial has completed the final follow-up assessments. The announcement, dated 19 November 2026, moves the trial into data entry and analysis. The study evaluates 64Cu-SAR-bisPSMA positron emission tomography for detecting prostate cancer recurrence.
Trial Design and Endpoints
AMPLIFY is a non-randomised, single-arm, open-label, multi-centre trial at sites across the United States and Australia. It enrols men with rising or detectable prostate-specific antigen after initial definitive treatment, at levels above 0.2 ng/mL. Its co-primary endpoints are participant-level correct detection rate and region-level positive predictive value, assessed for same-day and next-day imaging.
The trial began enrolment in May 2025 with a target of about 220 participants. The company says the target was reached in March 2026, and that the first participant was imaged at XCancer in Omaha, Nebraska, in the same month the trial began.
Regulatory Pathway
The data are intended to support applications to the US Food and Drug Administration for approval of 64Cu-SAR-bisPSMA as a diagnostic imaging agent in biochemical recurrence, under the AMPLIFY study, and in prostate cancer patients before definitive therapy, under the CLARIFY study. Clarity says the company has received Breakthrough Therapy Designation and Fast Track Designation for the product.
Dr Alan Taylor, Executive Chairperson, said the company is working with participating sites on entry of the final data and expects to start module submissions for its New Drug Application under the FDA’s rolling review process.
Market Context and Caveats
The company says the market opportunity for next-generation PSMA imaging is predicted to exceed US$3 billion by 2029. That figure is Clarity’s own estimate and is not drawn from an independent source in the announcement.
The release includes a disclaimer that 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA are unregistered products whose safety and efficacy have not been assessed by the FDA or the Therapeutic Goods Administration, and that there is no guarantee they will become commercially available.
Looking Ahead
The next milestone is topline data from AMPLIFY and CLARIFY, expected in the first half of CY2027. Those results will determine whether the trial meets its co-primary endpoints, and the planned NDA submissions will follow the data analysis.






Please wait processing your request...